Treatment of prediabetes

doi:10.4239/wjd.v6.i12.1207

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 12

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (14047)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-7) series, Tables (1-1) series.

Item

Count

PDF

1168

WORD

395

HTML

7794

Figures (1-7)

299

Tables (1-1)

144

Sum=9800

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

528

Download

1403

Sum=1931

Publishing Process of This Article

Item

Count

Browse

1132

Download

1184

Sum=2316

Sep 25, 2015 (publication date) through Apr 19, 2024

Times Cited of This Article

Times Cited (52)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Diabetes. Sep 25, 2015; 6(12): 1207-1222
Published online Sep 25, 2015. doi: 10.4239/wjd.v6.i12.1207

Table 1 Summary of pharmacologic intervention trials in individuals with impaired glucose tolerance

Study	n	Duration (yr)	Incidence of DM in control (%)	Relative risk reduction (%)
IDPP	269	2.5	18.3	26
USDPP	2151	2.8	11	31
USDPP	1172	0.9	11	75
TRIPOD	236	2.5	13.1	55
PIPOD	89	3	13.1	55
DREAM	5269	3	6.5	60
ACT NOW	602	2.8	6	72
CANOE	207	3.9	10.1	66
STOP NIDDM	1368	3.2	8.1	36
XENDOS	3305	4	2.2	37

DM: Diabetes mellitus; IDPP: Indian Diabetes Prevention Programme; USDPP: United StatesDiabetes Prevention Programme; TRIPOD: Troglitazon in the prevention of Diabetes; PIPOD: The pioglitazone in prevention of diabetes; DREAM: Diabetes Reduction Assessment with ramipril and rosiglitazone Medication; ACT NOW: Actos Now for the prevention of diabetes; CANOE: Canadian normoglycaemia outcomes evaluation; STOP NIDDM: Study to Prevent Non-Insulin-Dependent Diabetes Mellitus; XENDOS: Xenical in the prevention of Diabetes in Obese Subjects.

Citation: Kanat M, DeFronzo RA, Abdul-Ghani MA. Treatment of prediabetes. World J Diabetes 2015; 6(12): 1207-1222
URL: https://www.wjgnet.com/1948-9358/full/v6/i12/1207.htm
DOI: https://dx.doi.org/10.4239/wjd.v6.i12.1207